Chinese Trial Misconduct Delayed Bristol-Myers Medicine

Drugmakers have increasingly been turning to China for large clinical trials because they’re cheaper and there’s a bigger population of subjects to draw on.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.